This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siragusa, M. Articles by Stassi, G. Search for Related Content PubMed PubMed Citation Articles by Siragusa, M. Articles by Stassi, G.

MUC1 Oncoprotein Promotes Refractoriness to Chemotherapy in Thyroid Cancer Cells

¹ Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy; ² Department of Hematology and Oncology, Istituto Superiore di Sanità, Rome, Italy; and ³ Department of Experimental Oncology, Istituto Oncologico del Mediterraneo, Catania, Italy

Requests for reprints: Giorgio Stassi, Department of Surgical and Oncological Sciences, University of Palermo, Via Liborio Giuffrè 5, 90127 Palermo, Italy. Phone: 39-091-6553211; Fax: 39-091-6553294; E-mail: gstassi{at}tiscali.it.

Overexpression of MUC1 oncoprotein is frequently observed in cancer and contributes to confer resistance to genotoxic agents. Papillary, follicular, and anaplastic thyroid carcinomas are the three forms of thyroid epithelial cancer. Anaplastic tumors are less differentiated and extremely aggressive, characterized by a poor prognosis. Little is known about the role of MUC1 in thyroid cancer. We recently showed that autocrine production of interleukin (IL)-4 and IL-10 controls thyroid cancer cell survival, growth, and resistance to chemotherapy through activation of Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) and phosphatidylinositide 3'-OH kinase (PI3K)/Akt pathways. In the present study, we showed that MUC1 COOH-terminal subunit (MUC1-C) is overexpressed in all the histologic variants of thyroid cancer cells and localizes to mitochondria where it interferes with the release of mitochondrial proapoptotic proteins. Moreover, IL-4 and IL-10 promote the increase of MUC1-C expression levels in normal thyroid cells, whereas blockage of both cytokines or neutralization of JAK/STAT and PI3K/Akt pathways through the exogenous expression of SOCS-1 and Akt_K179M leads to a significant decrease of MUC1-C in primary thyroid cancer cells. Interestingly, down-regulation of MUC1 expression by direct targeting with RNA interference sensitizes anaplastic thyroid cancer cells to chemotherapy-induced apoptosis in vitro. Thus, MUC1 is a main component of the survival network acting in thyroid cancer and could be considered a key molecular target for sensitizing cancer cells to conventional or novel treatments. [Cancer Res 2007;67(11):5522–30]

This article has been cited by other articles:

				J. Huang, M.-I. Che, Y.-T. Huang, M.-K. Shyu, Y.-M. Huang, Y.-M. Wu, W.-C. Lin, P.-H. Huang, J.-T. Liang, P.-H. Lee, et al. Overexpression of MUC15 activates extracellular signal-regulated kinase 1/2 and promotes the oncogenic potential of human colon cancer cells Carcinogenesis, August 1, 2009; 30(8): 1452 - 1458. [Abstract] [Full Text] [PDF]